‘Transformative’ CAR-T therapy allows three people to receive kidney transplants

Three individuals with highly sensitized immune systems received kidney transplants using a CAR-T cell therapy on June 3, 2026, as reported by Nature. This innovative approach targets and eliminates the T cells responsible for rejecting foreign tissue, a significant hurdle for patients with a history of organ transplantation or other conditions that lead to immune system sensitization. Previously, these patients faced limited options, often relying on dialysis for survival due to the high likelihood of organ rejection. The CAR-T therapy, adapted from cancer treatments, involves genetically modifying a patient's own T cells to recognize and destroy the specific immune cells that would attack a transplanted kidney. This breakthrough offers a potential pathway for individuals previously deemed ineligible for transplantation, expanding the donor pool and improving quality of life for a patient group with critical unmet needs. The study published in Nature details the successful transplantation and the subsequent monitoring of the patients' immune responses, indicating the therapy's efficacy in preventing acute rejection.